124676-19-3

Basic information

• Product Name: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID
• Synonyms: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID;2-(1H-Benzotriazol-1-yl)-2-[(benzyloxycarbonyl)amino]acetic acid;alpha-[[(Phenylmethoxy)carbonyl]amino]-1H-benzotriazole-1-acetic acid;2-(1H-Benzo[d][1,2,3]triazol-1-yl)-2-(benzyloxycarbonylamino)acetic acid;α-[[(PhenylMethoxy)carbonyl]aMino]-1H-benzotriazole-1-acetic Acid;2-(1H-Benzo[d][1,2,3]triazol-1-yl)
• CAS NO: 124676-19-3
• Molecular Formula: C₁₆H₁₄N₄O₄
• Molecular Weight: 326.31
• Product Categories: pharmacetical
• Mol File: 124676-19-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 162-164℃
• Boiling Point: 596.4°C at 760 mmHg
• Flash Point: 314.5°C
• Appearance: /
• Density: 1.43
• Vapor Pressure: 4.51E-15mmHg at 25°C
• Refractive Index: 1.675
• Storage Temp.: 2-8°C
• PKA: 2.55±0.10(Predicted)
• CAS DataBase Reference: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID(124676-19-3)
• EPA Substance Registry System: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID(124676-19-3)

Safety Data

• Hazardous Substances Data: 124676-19-3(Hazardous Substances Data)

Usage

Uses

α-[[(Phenylmethoxy)carbonyl]amino]-1H-benzotriazole-1-acetic Acid is used in the synthesis of inhibitors of BET bromodomains. Also used in the synthesis of benzodiazepine-based SUMO-specific protein kinases.

InChI:InChI=1/C16H14N4O4/c21-15(22)14(20-13-9-5-4-8-12(13)18-19-20)17-16(23)24-10-11-6-2-1-3-7-11/h1-9,14H,10H2,(H,17,23)(H,21,22)

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 621-84-1 O-benzyl carbamate 
• 298-12-4 Glyoxilic acid 

Downstream Products

• 124676-23-9 α-(N-benzyloxycarbonyl)aminoglycine 
• 108895-98-3 benzyl 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamate 
• 1206716-08-6 [benzotriazol-1-yl(2-(4-chloro-benzoyl)-phenylcarbamoyl)-methyl]-carbamic acid benzyl ester 
• 1345046-75-4 C₂₃H₂₁N₅O₄ 
• 1345046-37-8 C₂₅H₂₁N₃O₄ 
• 1345046-38-9 C₂₆H₂₃N₃O₄ 
• 1345046-76-5 C₂₃H₁₉N₅O₄ 
• 1345046-74-3 C₁₉H₁₇N₃O₄ 
• 1355613-71-6 C₁₉H₁₉N₃O₄ 
• 1345046-36-7 C₂₆H₂₅N₃O₄ 
• 153826-05-2 [1-(2-Hydroxy-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 1584139-93-4 (S)-benzyl (9-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)carbamate 
• 1584648-43-0 benzyl (9-(((tert-butyldimethylsilyl)oxy)methyl)-5-(3-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
• 1584139-99-0 benzyl (9-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 

Relevant articles and documents

COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Discovery of clinical candidate BMS-906024: A potent pan-notch inhibitor for the treatment of leukemia and solid tumors

Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in